Podcasts about Immunotherapy

How can we better manage cardiovascular risk in patients with type 2 diabetes? Find out about this and more in today's PV Roundup podcast.

Featuring perspectives from Dr Stephen Liu, including the following topics: Introduction (0:00) Adjuvant and Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (1:18) Case: A man in his late 50s with metastatic NSCLC and no actionable mutations — Sandip Patel, MD (19:53) Case: A woman in her mid-60s with newly diagnosed adenocarcinoma of the lung — PD-L1 65% — Raji Shameem, MD (27:05) Case: A man in his early 70s with localized NSCLC and no actionable mutations — PD-L1 90% — Kapisthalam (KS) Kumar, MD (33:16) Case: A woman in her early 60s with extensive-stage small cell lung cancer — Ranju Gupta, MD (36:28) Thoughts for the Future: Part 1 (41:17) Case: A woman in her early 70s with Stage IIIB adenocarcinoma of the lung and an EGFR L858R tumor mutation — PD-L1 40% — Matthew Gubens, MD, MS (45:01) Thoughts for the Future: Part 2 (51:30) CME information and select publications

Dr Alan Bryce from the Mayo Clinic in Phoenix, Arizona, discusses current practice patterns and recent advances in the management of metastatic castration-resistant prostate cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue1).

On this episode of Think Like A Founder, SNP Co-Founder & CEO Maureen Taylor speaks with the Chief Scientific Officer, Jesse Cotari, and CEO, Peretz Partensky, of ImmuneBridge. They talk about taking ownership, being an outsider, and how life is practice for life. ImmuneBridge is an early-stage biotech company developing allogeneic immunotherapies for cancer. Before founding ImmuneBridge, Jesse was the Director of Analytics at Transfusion Health. He holds a Ph.D. in Immunology and Computational Biology from Cornell University. Also prior to ImmuneBridge, Peretz co-founded Cheetah Technologies, connecting restaurants and suppliers through an app with next-day delivery, and Sourcery, a smarter AP and AR automation solution built specifically for restaurants and the accounting firms that support them. He has a Ph.D. in Biophysics from UC San Francisco.Learn more about ImmuneBridge by reaching out to info@immunebridge.com Think Like A Founder is produced by SNP Communications in San Francisco, California. Learn more about the Think Like A Founder podcast and curriculum by visiting us at https://snpnet.com/tlaf/ or connect with Maureen Taylor on LinkedIn to continue the conversation there. Series Producer: Mike SullivanSound Design: Marc Ream Content and Scripting: Jaselin DrownProduction Coordinator: Natasha ThomasThanks also to Róisín Hunt, Selena Persiani-Shell, Jordan Bailey, Matt Johnson, John Hughes, and Renn Vara.

In this episode we turn our attention to Ralf Kleef a medical and naturopathic doctor specialized in Immunotherapy and Hyperthermia. Learn how he is treating an array of cancers through immunotherapy in the footsteps of the father of cancer immunotherapy, William B. Coley. Dr. Kleef takes us on an in-depth discussion on treatments and the success he is having with his patients. This is an episode you do not want to miss.   You can visit our following platforms:  Website: alltalkoncology.com, Facebook, Instagram, and YouTube

Immunotherapy has revolutionized cancer treatment over the last few decades, though not for glioblastoma — the most common and deadly malignant brain tumor. However, Northwestern Medicine neurosurgeon Adam Sonabend, MD, shares promising research on the potential benefits of immunotherapy for certain glioblastoma patients.

Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center discusses recent advances and future directions for the management of early-stage and advanced colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCAnal21/Issue1).

Arovella Therapeutics: Why is everyone talking “immunotherapy” for cancer? Listen to ASX-listed Arovella Therapeutics Managing Director Dr Michael Baker talk to Matt Birney on the Bulls N' Bears Report about Arovella's amazing technology that can temporarily remove blood cells from the body and reprogram them to seek and destroy cancer cells before being reinserted. See omnystudio.com/listener for privacy information.

Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarian21).

Dr Gregory Riely from the Memorial Sloan Kettering Cancer Center in New York City discusses recent advances and future directions in the management of patients with NSCLC and EGFR exon 20 insertion mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCEGFR21).

Featuring an interview with Dr Matthew Powell, including the following topics: Immunotherapy in Endometrial Cancer (0:00) Case: A woman in her late 50s with a history of Stage IVB serous carcinoma (20:44) Case: A woman in her early 60s with a history of Stage IB endometrial cancer (22:52) Case: A woman in her late 60s with a history of Stage IIIC2 carcinosarcoma (25:00) CME information and select publications

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:Atezolizumab plus bevacizumab as the current standard of careContraindications to atezolizumab plus bevacizumabThe current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the first-line settingPresenters:  Josep M. Llovet, MD, PhD, FAASLDProfessor of MedicineDirector, Mount Sinai Liver Cancer ProgramDivision of Liver DiseasesMount Sinai School of MedicineNew York, NYProfessor of ResearchLiver Unit, IDIBAPSHospital Clinic BarcelonaBarcelona, SpainUniv. Prof. Markus Peck-Radosavljevic, MD, MBAProfessor of Medicine, Medical University of ViennaVienna, AustriaDepartment Chair, Innere Medizin and GastroenterologieKlinikum Klagenfurt am WörtherseeKlagenfurt am Wörthersee, AustriaLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq

Dr Adil Daud from the UCSF Helen Diller Family Comprehensive Cancer Center discusses recent advances and future directions in the use of immunotherapy for the management of wild-type and BRAF-mutant melanoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMelanomaImmuno21).

Dr Andrew Evens from the Rutgers Cancer Institute in New Jersey discusses the management of newly diagnosed and advanced Hodgkin lymphoma in younger and older patients. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHL21).

Dr Matthew Powell from the Washington University School of Medicine in St Louis, Missouri, discusses therapeutic advances and novel investigational strategies for the management of endometrial cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEndometrial21).

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView's Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don't miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.

In the first part of the podcast, Dr. Justin Abbatemarco talks with Dr. Avi Nath, Director of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, about COVID-19 vaccines and neurology immunotherapy (00:56). In the second segment, Dr. Andy Southerland discusses disparities in the utilization of stroke interventions with Dr. Adam de Havenon (18:18).

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what's showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimensSecond-line therapeutic options after disease progression on an immunotherapy-based regimenImmunotherapy in patients with advanced NSCLC and brain metastasesDistinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsyFuture directions in immunotherapy for NSCLC, including the role of the gut microbiome in responsePresenters:Julie Brahmer, MD, MScProfessor of OncologyDirector, Thoracic OncologyCo-Director, Upper Aerodigestive Cancer ProgramBloomberg-Kimmel Institute for Cancer ImmunologySidney Kimmel Comprehensive Cancer CenterJohns Hopkins MedicineBaltimore, MarylandJarushka Naidoo, MB BCH BAO, MHSConsultant Medical OncologistBeaumont Hospital/RCSI University of Health SciencesDublin, IrelandAdjunct Assistant Professor of OncologySidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandContent based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.Link to full program:https://bit.ly/3CLC0Hd

Dr. Allison highlights everything from his proudest professional moments, to MD Anderson's Moon Shot program, to his musical talents, to next steps he's taking in cancer research.

Dr Arnon Kater from the Amsterdam University Medical Centers in Amsterdam discusses recent advances in the management of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCLL21/Issue1).

Dr Akila Viswanathan talks with Dr Wilfred Ngwa about both his work as the Director of the Global Health Catalyst, which aims to reduce cancer health disparities around the world, and his research pairing medical physics with immunotherapy. Learn more at globalhealthcatalystsummit.org

Dr Michael Savona from Vanderbilt University School of Medicine in Nashville, Tennessee, discusses recent advances and future directions in the management of myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMDS21/Issue2).

Ali Urman is ARK Invest's Genomic Revolution analyst, responsible for the company's research on Gene editing, DNA sequencing, Stem cell technologies & Immunotherapy. As of September 2021, ARK's AUM stood at a colossal $42.4 billion, spearheaded by investing legend and household name, Cathie Wood. To speak to ARK's Genomics analyst as a global pandemic thrusts Biotechnology into the spotlight was a huge privilege.And Ali doesn't disappoint. We discuss the Genomic revolution – how the sequencing of the first human genome cost $1bn and took 13 years, whereas today, that same process costs anywhere between $100-$1000, and takes just 1-2 days. Ali explains the transformative convergence of Next-generation DNA sequencing, Artificial Intelligence & CRISPR gene editing before we break down exactly how ARK picks their Genomics stocks! Enjoy the episodeFor an insight into Ark's research process, check out Ali's WIP articles on Medium - The latest two on Gene Editing, linked here:- https://medium.com/@aurmanARK/predicting-the-trajectory-of-prime-editing-lessons-from-base-editing-3351e58e53ff- https://medium.com/@aurmanARK/gene-editing-could-get-an-upgrade-e5e4aa0b6966 Thanks to Cofruition for consulting on and producing the podcast. Want further Opto insights? Check out our daily newsletter: https://www.cmcmarkets.com/en-gb/opto/newsletter------------------Past performance is not a reliable indicator of future results.CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment, or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction, or investment strategy is suitable for any specific person.The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.CMC Markets does not endorse or offer opinions on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein. for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

This week we are visiting Dr Stephanie Goff  at the NIH in  Bethesda, Maryland. Dr Goff is a surgical oncologist and a senior member of  a research team led by  Dr. Steven A. Rosenberg, a man widely regarded as the father of immunotherapy.  A friend, who knows  a thing or two about this place. is joining us on this trip. Her name is Judy Perkins, and she is the first MBC patient who has been  cured by a revolutionary immunotherapy treatment, known as adoptive cell therapy, that was administered by Dr Goff and her colleagues at the NCI.More info available on our website and sign up for our *NEW* newsblast www.ourmbclife.orgGot something to Share? Feedback?Email: ourmbclife@sharecancersupport.org Send us a voice recording via email or through speakpipe on our website.Follow on Facebook, Instagram, and Twitter @ourmbclife

Dr Jonathon Cohen from the Winship Cancer Institute of Emory University in Atlanta discusses recent advances and future directions in the use of CAR T-cell therapy for the management of non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTLymphoma21).

This chat offers a lesson on some of the latest pressing issues and trends in clinical research, bladder cancer, healthcare quality, electronic health records, and pharmaceutical industry relationships with academia from Dr. Guru Sonpavde, a cutting-edge, innovative medical oncologist and Bladder Cancer Director at the Dana Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School, member of Southwest Oncology Group (SWOG) and Bladder Cancer Task Force of the U.S. NCI Genitourinary Steering Committee. Highlights/Timeline: 4:45 – Perspectives on the physician patient relationship and how it has changed over the years 5:20 – Shared Decision-Making with patients 6:30 – Are patients more demanding than ever today and as a result present a challenge to physicians? 7:47 – Role of Innovative Clinical Research on the continuity of care? 10:08 – Memorable stories of novel treatments transforming patients' lives 10:42 – One of Dr. Sonpavde's patients was thought to be terminal having undergone 3 courses of chemotherapy for a cancer that has metastasized. This patient participated in a Phase I trial that combined a novel immunotherapy with an existing immunotherapy treatment and was given a very low likelihood of response yet the patient is still alive today in complete remission 2-years post treatment. 12:20 – Is our healthcare system designed to give physicians enough time to review patients' conditions to select the best course of therapy? It takes physicians a lot longer to enter data into EMR and requires more documentation than ever before 14:38 There is a huge unmet need in novel AI technology that is able to transcribe physician orders, comments accurately and patient level medical in order to close down the barrier between the patient and healthcare provider. 15:40 – Latest emerging treatments Dr. Sonpavde is most excited about in Bladder Cancer 16:23 – 1. Immunotherapy with Immune check-point inhibitors are a promising class of drugs that unleash immune T cells to fight the cancer in patients whose cancer progresses after the conventional platinum-based chemotherapy or even as first-line for metastatic cancer in patients who express PD-L1 protein or are ineligible for platinum-based chemotherapy. 2. Antibody-Drug Conjugates that are essentially a smart way of delivery of strong chemotherapy with more specific targeting of the tumor. 3. Erdafitinib, an FGFR3 inhibitor that works in patients who express this FGFR3 mutation that works in only 20 percent of patients. 4. Combining immunotherapy with Antibody Drug Conjugates is a very promising new approach 18:55 – Are there any particular new areas of research that are not addressed in bladder cancer? 19:31 – We still do not fully understand the biology of bladder cancer and have to improve our efforts in delivering the right treatment to the right patient - precision medicine. 1) We do not know who will benefit most from cisplatin chemotherapy 2) or who will benefit most from immunotherapy, and 3) we do not know the group of patients that will NOT benefit AT ALL from immunotherapy or chemotherapy because those are the populations that need the treatments the most. Thus we need biomarkers to predict tumor progression not just response to medication. 21:52 – What is Dr. Sonpavde's opinion about invasive versus non-invasive screening/testing in Bladder Cancer? 24:32 – Are Bladder Cancer patients expecting simpler methods of screening and longer survival? 28:47 – How can the Medical Affairs and R & D division of the pharmaceutical and medical device industries improve the quality of research to anchor it to patient outcomes in the future? 31:00 – What is one detail about clinical research would you teach patients to better manage their expectations? 33:15 – Are we improving in the transparency and speed of generating and communicating clinical trial results in healthcare? 37:16 – What is one specific medication on which you are working on at the moment? --- Support this podcast: https://anchor.fm/alloutcoach/support

Dr Cristina Rodriguez from the Fred Hutchinson Cancer Research Center in Seattle discusses the current management of head and neck cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHeadNeck21).

Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses the pathogenesis and management of myeloproliferative neoplasms. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMPN21).

Stomach cancer, also known as gastric cancer, can affect any part of the stomach. In most of the world, stomach cancers form in the main part of the stomach. But in the U.S., stomach cancer is more likely to affect the area where the esophagus meets the stomach. This area is called the gastroesophageal junction. Where the cancer occurs in the stomach is one factor doctors consider when determining treatment options. Treatment usually includes surgery to remove the stomach cancer. Other treatments may be recommended before and after surgery, including immunotherapy. "Over the past three years, we've incorporated immunotherapy into the treatment of stomach cancer. This type of therapy boosts the immune system to go after the cancer," says Dr. Lionel Kankeu Fonkoua, a Mayo Clinic medical oncologist. "Cancer cells are very smart and find ways to evade or put brakes on the immune system. Immunotherapy is designed to release those brakes and unleash the immune system to go after the cancer. And when that's effective, we've seen some dramatic and durable responses in some of these patients." November is Stomach Cancer Awareness Month. On the Mayo Clinic Q&A podcast, Dr. Kankeu Fonkoua discusses risk factors, the latest treatments and steps you can take to prevent stomach cancer.

Cancer, Incorporated And Immunotherapy: The Battle Within - Ralph Moss - Offstage Interview 2021 Ralph Moss • https://www.mossreports.com/ • Book - Cancer, Incorporated and Immunotherapy: The Battle Within The medical writer Ralph W. Moss, PhD, has written or edited twelve books and four film documentaries on questions relating to cancer research and treatment. Dr. Moss is a graduate of New York University (BA, cum laude, Phi Beta Kappa, 1965) and Stanford University (MA, 1973, PhD, 1974, Classics). He is the former science writer and assistant director of public affairs at Memorial Sloan-Kettering Cancer Center in New York (1974-1977). Since leaving Sloan-Kettering in 1977, Moss has independently evaluated the claims of conventional and non-conventional cancer treatments all over the world. He currently writes Moss Reports, detailed reports on the most common cancer diagnoses and provides informational and personalized consultations for cancer patients and their families. In 2019, he wrote The Ultimate Guide to Cancer: DIY Research, to help lay people research their own cancers. This 50-page report is available free of charge at the mossreports.com website. Passionate believers in whole food plant based diets, no chemicals, minimal pharmaceutical drugs, no GMO's. Fighting to stop climate change and extinction. Connect with The Real Truth About Health: Sign Up for our Membership Club and Get 30 Days Free

Hi, everybody! On this Halloween weekend episode, Kristin, Rodney, and George talk about Dune, Dopesick, and Halloween Kills but the scariest thing may be Big Insurance. Plus, ear piercings, tattoos, and Art Nerrd - Volleyball Dad! Our friends Lauren and Sarah at the Enough Wicker podcast want to hear about your favorite moments from the Golden Girls. Go to https://www.enoughwicker.com/contest and record up to five minutes of scholarly observations about a moment in the show that provoked thought, deep emotion, or just made you laugh for a special reason. You'll have an opportunity to have your thoughts featured in an upcoming very special episode. Plus, there's a chance to win Funko Pops and all kinds of great prizes. Thank you all for being a friend. Please subscribe, share, rate and review the show. Thank you for all your comments on Twitter and Instagram. https://twitter.com/@MeanwhileATP https://www.instagram.com/meanwhileatp http://www.meanwhileatthepodcast.libsyn.com  https://www.facebook.com/meanwhileatthepodcast Rodney (AKA Art Nerrd): https://www.instagram.com/theartnerrd https://twitter.com/@artnerrd https://www.facebook.com/artnerrd https://shop.spreadshirt.com/artnerrd Kristin: https://www.instagram.com/klu4973 https://twitter.com/@klu4973

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Katherina Grette and Nathaniel Jones to discuss racial inequities in immunotherapy trials and their article, “Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers,” which is the Lead Article in IJGC's November 2021 issue. (https://ijgc.bmj.com/content/early/2021/09/21/ijgc-2021-002557) Dr. Katherine Grette attended medical school at the University of Washington, then completed her residency in Obstetrics and Gynecology at the University of South Alabama prior to joining faculty. She currently practices as a generalist and serves as the Assistant Director of Resident Research for the department. Dr. Nate Jones completed residency at Mountain Area Health Education Center in Asheville, NC followed by fellowship in Gynecologic Oncology at New York Presbyterian Hospitals: Columbia and Cornell. He currently serves as Assistant Professor in Gynecologic Oncology at the University of South Alabama Mitchell Cancer Institute. His research interests center on targeted cancer therapies, molecular and genomic characteristics of gynecologic malignancies, and addressing racial disparities in gynecologic cancer care. Highlights •Minority women are poorly represented in immunotherapy clinical trials for breast and gynecologic cancers •Enrollment of black women is especially low, accounting for only 5% of participants •Minority participation in clinical trials must increase to improve equity in health outcomes @natejones333 / @katgrette / @usamci

ONS member Kristi Orbaugh, RN, MSN, RNP, AOCN®, nurse practitioner for Community Hospital Oncology Physicians in Indianapolis, IN, and member of the Central Indiana ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss patient education prior to and during immunotherapy. This is a continued conversation from a previous episode that discussed findings from an ONS focus group that Orbaugh facilitated in August 2021; we've linked that in the episode notes. This podcast episode is supported by an educational grant from AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Episode Notes  Check out these resources from today's episode:   NCPD contact hours are not available for this episode.  Oncology Nursing Podcast Episode 172: Address Knowledge Gaps in Evidence-Based Precision Medicine Care  Previous Oncology Nursing Podcast episodes on immunotherapy  ONS Voice article: New Patient Education Formats Help Nurses Connect Patients to Individualized Resources  ONS Voice article: Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors  ONS Voice article: Tailored Education Improves Patient Satisfaction and Comprehension  ONS course bundle: Immuno-Oncology for the Oncology Nurse Case Studies  Immuno-Oncology Learning Library  American Cancer Society patient education resources   ASCO patient education materials  National Comprehensive Cancer Network guidelines on managing immunotherapy-related toxicities  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. 

Dr Michael Mauro from the Memorial Sloan Kettering Cancer Center in New York City, New York, discusses the management of chronic myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCML21).

"To undergo OIT or not to undergo OIT? "That is the question many parents of kiddos with food allergy are now considering.If you have ever wondered what it's like to be the parent of a  kiddo with food allergy and make this decision, then don't miss this episode.Pam and Dr. Hoyt interview the mom of one of Dr. Hoyt's patients, and they talk about the experience with early peanut oral immunotherapy. Hear from this mom what the process was really like!What's your food allergy question? Submit it and learn more about food allergy and YOUR kiddo through the Food Allergy and Your Kiddo website: https://foodallergyandyourkiddo.comAre you in need of an allergist in your area? Check out these allergist finder tools from the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology:AAAAI Allergist Finder: https://allergist.aaaai.org/find/ACAAI Allergist Finder: https://acaai.org/locate-an-allergistDoes your kiddo's school need help with medical emergency response planning? Check out Code Ana, the non-profit program that is equipping schools for medical emergencies like anaphylaxis.www.CodeAna.orgVisit Dr. Hoyt and Pam on Facebook!https://www.facebook.com/foodallergyandyourkiddoListen to the Food Allergy and Your Kiddo Podcast where ever you listen to podcasts, such as:Apple PodcastsGoogle PodcastsSpotify

Check out our sponsors:  Better Help: Get 10% off your first month at https://betterhelp.com/impacttheory Athletic Greens: Go to athleticgreens.com/impact and receive a FREE 1 year supply of Vitamin D AND 5 free travel packs with your first purchase! Upstart: UPSTART.com/IMPACT Nutrisense: For $50 off, go to trynutrisense.com/Impact and use code IMPACT ChiliSleep: Get 20% off at chilisleep.com/IMPACT Being open minded to new science, new research and medical breakthroughs is always a bonus. Too often it's thought that health is for the rich or privileged that can afford high quality care, but when researchers and physicians begin to share how easy and accessible better health is for everyone, it's time to really pay attention. Dr. William Li is an internal medicine doctor from the Harvard Medical School Faculty that studies angiogenesis, and is the author of the best-selling book, Eat To Beat Disease. Dr. Li is breaking down the 5 natural body defenses protecting you at all times, even right now, and exactly how powerful foods are that can prevent disease in your body. This interview feels like part of the missing chronicles of optimizing your health to a level you never knew existed, and there's nothing complicated about it.   Order Dr. William Li's book, Eat to Beat Disease: https://amzn.to/3DWuDhT   SHOW NOTES:   0:00 | Introduction William Li 0:53 | Defining Real Health 4:39 | 5 Health Defense Systems 11:00 | Hiding Cancer in the Body 18:00 | Cellular Profiling Cancer 23:07 | Microbiome & Immune System 33:03 | Medicinal Food Power 40:49 | Explaining Angiogenesis 45:15 | Eating to Beat Disease   QUOTES:   “In most people's minds, including mine, not being sick is kind of the default definition of being healthy. But that is very problematic” [2:40]   “Health is not just the absence of disease, it is the result of our body's own hardwired defense systems, health defense systems that we're born with.” [3:09]   “Organic coffee has more bioactives than the pesticide treated coffee because the insects, the natural things in the environment cause it to create more natural health defenses.” [39:36]   “Eating to beat disease is not just picking a particular disease and trying to figure out what the recipe is that the one size fits all. But it's really a journey that we have our whole lives.” [46:24]   Follow William Li: Website: https://drwilliamli.com/ YouTube: https://www.youtube.com/channel/UCREeA-1pswf4RTeYIKdAoBg/featured Twitter: https://twitter.com/drwilliamli Instagram: https://www.instagram.com/drwilliamli/ Facebook: https://www.facebook.com/drwilliamli/